Hatteras Venture Partners related stories
All articles and analysis
Lumira Capital invests in $33 mln Series B funding of G1 TherapeuticsG1 Therapeutics Inc has raised US$33 million in a Series B financing led by Eshelman Ventures and RA Capital Management. Joining the round were new investors, including Canadian life sciences venture capital firm Lumira Capital. Other investors included Tavistock Life Sciences' Boxer Capital, Hatteras Venture Partners, MedImmune Ventures and Mountain Group Capital. Based in Research Triangle Park, North Carolina, G1 Therapeutics is a pharmaceutical company developing small-molecule therapies to address significant unmet needs in oncology. Its lead program, G1T28, is currently being evaluated in Phase 1a clinical trials.
LTI picks up $20 mln Series ACambridge, Massachusetts-based Lysosomal Therapeutics Inc, which develops molecules to treat neurodegenerative diseases, has closed $20 million in Series A funding. The backers in this round included Atlas Venture, Hatteras Venture Partners, Lilly Ventures, Sanofi-Genzyme BioVentures, Roche Venture Fund, Partners Innovation Fund and Orion Equity Partners.
- Clinipace picks up $50 mln
Morrisville, North Carolina-based Clinipace Worldwide, a digital clinical research organization, has raised $50 million in funding. Virgo Investment Group led the round with participation from other investors that included Crestline Investors, Morgan Stanley Expansion Capital, Hatteras Venture Partners, Harbert Venture Partners and Mario Family Funds. Perella Weinberg Partners served as an advisor on the transaction.
- Viamet Pharma raises $60 mln
Viamet Pharmaceuticals Holdings said Tuesday it closed a $60 million Series D financing provided by Brandon Point Industries Ltd. working with Woodford Investment Management. Current investors includes Novartis Venture Fund, Lilly Ventures, Hatteras Venture Partners, Intersouth Partners, Lurie Holdings and Astellas Venture Management. Durham, N.C.-based Viamet Pharma develops antifungal agents using a metalloenzyme medicinal chemistry platform.
- Clearside Biomedical picks up $16 mln Series B
Clearside Biomedical said Monday that it has raised $16 million in Series B financing. The investors included RusnanoMedInvest, Hatteras Venture Partners, Santen Pharmaceuticals Co. Ltd., Mountain Group Capital and Georgia Research Alliance Venture Fund. Headquartered in Alpharetta, GA, Clearside Biomedical is a clinical-stage biopharmaceutical firm focused on treating eye diseases.
- Edison Partners promotes three
The growth equity firm has promoted three people to partner
- Edison Partners and Hatteras Venture Partners back Clinverse
Edison Partners said Tuesday that it is leading a $9 million funding round in Clinverse. Other investors include Hatteras Venture Partners. Based in Durham, NC, Clinverse is a provider of automated financial management technology solutions for clinical trials.
- Atlas Venture leads seed round for Lysosomal Therapeutics
Lysosomal Therapeutics has secured $4.8 million in seed funding. Atlas Venture led the round with participation from Hatteras Venture Partners, Lilly Ventures, Sanofi-Genzyme BioVentures, Roche Venture Fund, Partners Innovation Fund and Orion Equity Partners. Headquartered in Cambridge, Mass., Lysosomal Therapeutics develops molecules to be used to treat neurodegenerative diseases.
- VC-backed G1 Therapeutics appoints executive chairman of board of directors
G1 Therapeutics said Tuesday that it has named Dr. Seth Rudnick as executive chairman of its board of directors. The appointment is effective immediately. Dr. Rudnick is recently retired from Canaan Partners. Based in Chapel Hill, North Carolina, G1 is a pharmaceutical company focused on cancer therapy and biodefense applications. It is backed by MedImmune Ventures, Hatteras Venture Partners and Mountain Group Capital.
- Sideris Pharmaceuticals racks up $32 mln, also could be acquired by Novartis for up to $300 mln
Sideris Pharmaceuticals said Tuesday that it has closed $32 million in Series A financing. MPM Capital led the round with participation from Hatteras Venture Partners and Osage University Partners. In addition to the financing, Sideris has inked an agreement with Novartis Pharmaceuticals that grants Novartis the exclusive right to acquire Sideris in a transaction that could reach up to $300 million. Also, Sideris has named Dr. Ansbert Gadicke and Dr. Kazumi Shiosaki, managing directors of MPM Capital and Dr. Doug Reed, general partner of Hatteras Venture Partners, to the Sideris board of directors. Sideris Pharmaceuticals is a biopharmaceutical company that develops treatments for transfusion-related iron overload.